Medicine for treating coronary heart disease and myocardial infarction and taking method thereof

Abstract

The invention discloses a medicine for treating coronary heart disease and myocardial infarction and a taking method thereof. The medicine comprises the following components in specific parts by weight: Yunnan Baiyao semen saussureae, Liushen pills, sinew-strengthening tablets, vitamin B1 and diclofenac sodium enteric-coated tablets. The medicine is orally taken three times a day, one treatment course comprises seven days, and one treatment course every year. According to the principle, all the components have a synergistic effect in the aspects of relieving spasm, eliminating thrombus, dredging collaterals, relieving pain, promoting energy metabolism, relieving inflammation and edema and the like. The medicine has the advantages that the treatment effect is remarkable, myocardial blood supply can be improved, peduncle formation is avoided, relapse is prevented and sequelae are improved when patients with embolism take the medicine; the medicine is convenient to take, and the medicine taking frequency and period are greatly reduced; the safety is high and the side effect is small. Clinical studies show that in a grouped experiment of 200 patients, compared with a control group, the experimental group has significant difference (Plt, Plt) in the aspects of symptoms, electrocardiogram, myocardial zymogram, recurrence rate, sequelae improvement and the like; 0.05), and the traditional Chinese medicine composition has great clinical popularization value.

Description

Technical Field

[0001] The present invention relates to the technical field of medicine, and in particular to a medicine for treating coronary heart disease, angina pectoris and myocardial infarction and a method for taking the medicine. Background Art

[0002] Coronary heart disease, angina pectoris, and myocardial infarction are cardiovascular diseases that pose a serious threat to human health, with their incidence increasing year by year. According to statistics, a large number of patients die from coronary heart disease, angina pectoris, myocardial infarction, and their related complications every year worldwide.

[0003] Currently, there are numerous clinical treatments for coronary heart disease, angina pectoris, and myocardial infarction, including medication, interventional therapy (such as stent implantation), and surgical intervention (such as coronary artery bypass grafting). Medication is the foundation, with commonly used drugs including antiplatelet drugs, statins, and angiotensin-converting enzyme inhibitors. While these drugs can alleviate symptoms and reduce the risk of cardiovascular events to a certain extent, long-term use may have significant side effects. For example, antiplatelet drugs may increase the risk of bleeding.

[0004] While interventional therapy and surgery can effectively improve myocardial blood flow, they are not perfect. Stent implantation carries the risk of in-stent restenosis, requiring patients to take long-term antiplatelet medications after surgery. The high cost of surgery places a heavy financial burden on patients. Coronary artery bypass grafting is a more invasive procedure, requiring a long recovery time and requiring a high level of physical fitness, which some patients may not be able to tolerate.

[0005] For patients with myocardial infarction and cerebral infarction, preventing recurrence and improving sequelae are also key points and difficulties in clinical treatment. Existing treatment methods are not satisfactory in this regard. Patients often have to endure the pain caused by sequelae for a long time, and their quality of life is seriously reduced. Therefore, the development of a safe, effective, and convenient drug that can effectively treat coronary heart disease, angina pectoris, and myocardial infarction, while also preventing recurrence of myocardial infarction and cerebral infarction and improving sequelae, as well as a method of administration, has important clinical significance and social value. Summary of the Invention

[0006] The present invention aims to solve the above technical problems and provide a medicine for treating coronary heart disease and myocardial infarction and a method of taking the medicine.

[0007] To solve the above technical problems, the present invention provides a technical solution: a drug for treating coronary heart disease and myocardial infarction, comprising Yunnan Baiyao Baoanzi, Liushen Pills, Qiangjinsong Tablets, Vitamin B1, and Diclofenac Sodium Enteric-coated Tablets.

[0008] Furthermore, the following components are included in parts by weight: 1-2 parts of Yunnan Baiyao Baoanzi, 10-20 parts of Liushen Pills, 1-2 parts of Qiangjinsong Tablets, 1-3 parts of Vitamin B1, and 1-3 parts of Diclofenac Sodium Enteric-coated Tablets.

[0009] Furthermore, the following components are included in parts by weight: 1 part of Yunnan Baiyao Baoanzi, 12 parts of Liushen Pills, 1 part of Qiangjinsong Tablets, 2 parts of Vitamin B1, and 2 parts of Diclofenac Sodium Enteric-coated Tablets.

[0010] A method for taking a medicine for treating coronary heart disease and myocardial infarction is to take it orally three times a day, with seven days as a course of treatment, and one course of treatment can be taken every year.

[0011] The advantages of the present invention compared with the prior art are:

[0012] 1. Significant therapeutic effect

[0013] The drug of this invention, through the synergistic action of multiple components, can effectively improve coronary blood circulation, increase myocardial blood supply, and alleviate myocardial ischemia and hypoxia, thereby playing a beneficial role in treating coronary heart disease, angina pectoris, and myocardial infarction. Clinical studies have shown that patients treated with the drug of this invention have significantly reduced the number of angina attacks, significantly improved ST-T segment changes on electrocardiograms, and normalized myocardial enzyme profile indicators.

[0014] For patients with cardiovascular and cerebrovascular diseases, medication before an infarction occurs can effectively prevent the occurrence of myocardial infarction and cerebral infarction. For patients with myocardial infarction and cerebral infarction, the drug of the present invention can effectively prevent recurrence. By improving endothelial function, regulating blood lipids, and inhibiting thrombosis, the risk of cardiovascular events is reduced. At the same time, the ingredients in the drug can also promote the recovery of neurological function, improve patients' sequelae symptoms such as limb numbness and speech impairment, and improve their quality of life.

[0015] 2. Easy to take

[0016] The drug of the present invention is taken orally three times daily for a seven-day course of treatment, with one course of treatment per year being sufficient. Compared to traditional treatments that require long-term daily medication, this significantly reduces the number of medications patients take and the duration of medication, thereby improving patient compliance. Patients no longer need to take medication frequently, which reduces their psychological and financial burdens and also reduces the risk of poor treatment outcomes due to missed doses.

[0017] 3. High security

[0018] The ingredients used in the drug of this invention are all commonly used clinical drugs with extensively validated safety. Within a reasonable dosage range, the drug has minimal side effects and is well tolerated by patients. Compared with some interventional therapies and surgical procedures, it avoids surgical risks and postoperative complications, providing a safer treatment option for patients. DETAILED DESCRIPTION

[0019] In order to make the technical problems, technical solutions and beneficial effects to be solved by the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0020] 1. Working principle of the present invention:

[0021] The medicine for treating coronary heart disease, angina pectoris and myocardial infarction of the present invention comprises Yunnan Baiyao Baoanzi, Liushen Pills, Qiangjinsong Tablets, Vitamin B1 and Diclofenac Sodium Enteric-coated Tablets.

[0022] More specifically, calculated by weight, the medicine of the present invention includes the following components: 1-2 parts of Yunnan Baiyao Baoshizi, 10-20 parts of Liushen Pills, 1-2 parts of Qiangjinsong tablets, 1-3 parts of vitamin B1, and 1-3 parts of diclofenac sodium enteric-coated tablets.

[0023] Further preferably, calculated by weight, the medicine of the present invention includes the following components: 1 part of Yunnan Baiyao Baoanzi, 12 parts of Liushen Pills, 1 part of Qiangjinsong Tablets, 2 parts of Vitamin B1, and 2 parts of Diclofenac Sodium Enteric-coated Tablets.

[0024] The method for taking the medicine of the present invention is: oral administration three times a day, seven days as a course of treatment, and one course of treatment can be taken every year.

[0025] Yunnan Baiyao Baoshizi: Yunnan Baiyao Baoshizi has the efficacy of removing blood stasis and stopping bleeding, promoting blood circulation and relieving pain, and detoxifying and reducing swelling. In the present invention, its main function is to promote blood circulation and remove blood stasis, improve coronary blood circulation, increase myocardial blood supply, thereby alleviating myocardial ischemia and hypoxia, and playing a protective role on the myocardium. At the same time, its blood circulation and blood stasis-removing properties help prevent thrombosis and reduce the risk of vascular blockage, which is of great significance for the treatment of coronary heart disease, angina pectoris, and myocardial infarction, and for preventing recurrence.

[0026] Liushen Pills: Liushen Pills have cooling, detoxifying, anti-inflammatory, and analgesic properties. Modern research indicates that Liushen Pills possess certain cardiovascular protective properties. They can regulate blood lipids, reduce blood viscosity, and reduce lipid deposition in blood vessel walls, thereby helping to prevent the further development of atherosclerosis. Furthermore, Liushen Pills possess anti-inflammatory properties, alleviating inflammatory damage to vascular endothelial cells, maintaining endothelial integrity, and thus improving cardiovascular function.

[0027] Qiangjinsong tablets: Qiangjinsong tablets are primarily used to relieve muscle tension and pain. In the treatment of coronary heart disease, angina pectoris, and myocardial infarction, patients often experience chest pain due to myocardial ischemia and hypoxia, which may also be accompanied by tension in the surrounding muscles. Qiangjinsong tablets can relieve muscle tension, alleviate pain symptoms, and improve patient comfort. Furthermore, relieving muscle tension helps improve blood circulation, indirectly aiding in the recovery of cardiac function.

[0028] Vitamin B1: Vitamin B1 participates in glucose metabolism and plays a vital role in maintaining the normal function of the nervous system. In the cardiovascular system, vitamin B1 promotes energy metabolism in myocardial cells and enhances myocardial contractility. It also improves nerve conduction, regulates the heart's autonomic nervous system, and reduces the occurrence of arrhythmias. This has positive implications for restoring cardiac function and improving overall condition in patients with coronary heart disease, angina pectoris, and myocardial infarction.

[0029] Diclofenac Sodium Enteric-Coated Tablets: Diclofenac Sodium Enteric-Coated Tablets are a nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects. In the present invention, their primary function is to alleviate the inflammatory response at the site of myocardial infarction and relieve pain. Inflammation plays a key role in the development and progression of coronary heart disease, angina pectoris, and myocardial infarction. Diclofenac Sodium Enteric-Coated Tablets inhibit the release of inflammatory mediators, reducing inflammatory damage to myocardial cells and contributing to their repair and regeneration.

[0030] The various components in the medicine of the present invention work together through different mechanisms of action to jointly play the role of treating coronary heart disease, angina pectoris, and myocardial infarction. Yunnan Baiyao Baoshengzi and Liushen Pills treat the root causes of coronary heart disease by improving blood circulation, preventing thrombosis, and regulating blood lipids; Qiangjinsong Tablets and Diclofenac Sodium Enteric-coated Tablets mainly relieve the patient's pain symptoms and improve the patient's quality of life; Vitamin B1 plays an auxiliary role in the recovery of cardiac function by promoting myocardial cell energy metabolism and regulating cardiac autonomic nervous function. These components cooperate with each other to form an organic whole, jointly achieving the purpose of treating coronary heart disease, angina pectoris, myocardial infarction, preventing the recurrence of myocardial infarction and cerebral infarction, and improving sequelae.

[0031] 2. Implementation Methods:

[0032] Case selection: 200 patients aged 45-75 years who met the diagnostic criteria for coronary heart disease, angina pectoris, and myocardial infarction were selected and randomly divided into two groups, the experimental group and the control group, with 100 cases in each group.

[0033] Treatment:

[0034] Experimental group: The drug of the present invention was administered orally three times a day, with an appropriate amount of the drug preparation prepared according to the above formula taken each time (the specific dosage was determined according to different dosage forms and specifications), seven days as a course of treatment, and one course of treatment was taken each year.

[0035] Control group: traditional drugs for treating coronary heart disease, such as aspirin, atorvastatin, etc., were taken according to the regular dosage and course of treatment.

[0036] Observation indicators:

[0037] During treatment, regularly observe the patient's angina attack frequency, pain intensity, duration and other symptom changes.

[0038] Electrocardiograms were performed before and after treatment to observe changes in the ST-T segment.

[0039] Myocardial enzyme spectrum indicators such as creatine kinase isoenzyme (CK-MB) and troponin I (cTn I) were detected before and after treatment.

[0040] During the one-year follow-up, the recurrence of myocardial infarction and cerebral infarction as well as the improvement of sequelae of the two groups of patients were observed.

[0041] Treatment results:

[0042] Symptom improvement: The number of angina attacks in the experimental group was significantly reduced, the pain intensity was alleviated, and the duration was shortened. Compared with the control group, the differences were statistically significant (P<0.05).

[0043] ECG improvement: After treatment, the ST-T segment changes in the experimental group were significantly improved, the ST segment rebounded, and the T wave inversion became shallower or returned to normal. Compared with the control group, the improvement was more obvious (P<0.05).

[0044] Myocardial enzyme spectrum indicators: After treatment, the myocardial enzyme spectrum indicators of the experimental group decreased significantly and approached normal levels. Compared with the control group, the difference was statistically significant (P<0.05).

[0045] Recurrence and improvement of sequelae: After one year of follow-up, the recurrence rate of myocardial infarction and cerebral infarction in the experimental group was significantly lower than that in the control group, and the improvement of sequelae was also significantly better than that in the control group (P<0.05).

[0046] The present invention and its implementation methods are described above. This description is not restrictive. If ordinary technicians in this field are inspired by it and design structural methods and embodiments similar to the technical solution without creatively designing them without departing from the purpose of the invention, they should all fall within the scope of protection of the present invention.

Claims

1. A drug for treating coronary heart disease and myocardial infarction, characterized in that: Including Yunnan Baiyao Baoanzi, Liushen Pills, Qiangjinsong Tablets, Vitamin B1, and Diclofenac Sodium Enteric-coated Tablets.

2. The drug for treating coronary heart disease and myocardial infarction according to claim 1, characterized in that: The composition is calculated by weight as follows: 1-2 parts of Yunnan Baiyao Baoanzi, 10-20 parts of Liushen Pills, 1-2 parts of Qiangjinsong Tablets, 1-3 parts of Vitamin B1, and 1-3 parts of Diclofenac Sodium Enteric-coated Tablets.

3. The drug for treating coronary heart disease and myocardial infarction according to claim 1, characterized in that: The composition is calculated by weight and includes: 1 part of Yunnan Baiyao Baoanzi, 12 parts of Liushen Pills, 1 part of Qiangjinsong Tablets, 2 parts of Vitamin B1, and 2 parts of Diclofenac Sodium Enteric-coated Tablets.

4. A method for taking a drug for treating coronary heart disease and myocardial infarction, characterized in that: Specifically: take orally three times a day, seven days as a course of treatment, and one course of treatment per year.